Health
Continue to drive global industrial innovation to
create a medical-grade, one-stop, all-scenario health ecosystem
In 2024, a total of 16 indications of 7 innovative drugs/biosimilars independently developed and licensed-in by Fosun were approved for launch;
8 innovative drugs/biosimilars entered the pre-launch approval/critical clinical stage; 18 innovative drugs/biosimilar projects initiated clinical trials
Medical aesthetics, respiratory health, professional medical devices, and medical diagnosis
Focusing on high-quality medical and professional services, the offerings include combined insurance,
health consumption, and wellness solutions, designed to create a comprehensive closed-loop solution
A Core Company In The Health Segment
A global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China
Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services.
As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
-
40.91billion
Revenue in 2024
-
11.30billion
Overseas revenue, covering markets in the U.S., Europe, Africa, India, and Southeast Asia
-
5.55billion
R&D investment in 2024, with over 80 major pipeline projects on innovative drugs and biosimilars (calculated by indications)
-
286projects
The pharmaceutical segment submitted 220 patent applications and obtained 66 licensed invention patents authorization
-
Pharmaceuticals
Innovative drugs
Mature products and manufacturing
Vaccine -
Medical Devices and Medical Diagnosis
Medical devices
Medical diagnosis -
Healthcare Services
Online medical service platform
Offline medical institutions
(including rehabilitation medical institutions)
